November 2020 Vol. 8 No.11

Abstract
Full text
Reprint (PDF) (609 KB)

Search Pubmed for articles by:
 

Original Research Article

Effect Assessment of Human Immunodeficiency Virus co infection on Serum Level of Cytokines and Chemokines of Multidrug Resistant-tuberculosis Patients in Tanzania

John Chale Mgogwe^1,3*, Hadija Hamis Semvua¹, Oliva Safari Massay⁴, Balthazar Nyombi¹, Jaffu Otheniel Chilongola^1,2

¹Kilimanjaro Christian Medical University College P. O. Box 2240, Moshi, Tanzania.
²Kilimanjaro Clinical Research Institute, P. O. Box 2236, Moshi, Tanzania.
³Kibong`oto Infectious Diseases Hospital, P. O. Box 12, Sanya Juu, Kilimanjaro, Tanzania
⁴Catholic Dioceses of Mbulu, P.O. Box 49, Mbulu, Manyara, Tanzania

*Corresponding Authors E-mail: mgogwej@yahoo.com

Received: 09 November 2020  I  Accepted: 26 November 2020  I  Published: 28 November 2020  I  Article ID: MRJMMS-20-197
Copyright © 2020 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0.

Abstract

Multidrug-resistant tuberculosis (MDR-TB) with human immunodeficiency virus (HIV) immunologic state which is marked by chemokine and cytokine distortion is indicated by boosting the defense stimulation to a patient. The effect of coexisting infections on the MDR-TB patient with HIV is still not fully explored, hence this study aims to assess the serum level of chemokine/cytokine indices in MDR-TB patients with HIV or without HIV infection. We assessed serum levels of chemokines and cytokines from 92 MDR-TB patients with HIV and 106 MDR-TB patients without HIV before initiation of treatment and after six months of treatment with second-line anti-TB plus ARV drugs and MDR-TB without HIV with second-line anti TB drugs applying Luminex assay to assess the effect of HIV on serum level of cytokines and chemokines of MDR-TB patients before and after initiation of intensive second-line anti TB treatment for MDR-TB and second line anti TB plus ARV drugs for MDR-TB with HIV infection. The proportion of IFN-γ/IL−4 and IFN-γ/IL−10 indicated by a notable elevation following medication in MDR-TB patients without HIV but not in MDR-TB patients with HIV which might point to extended harm of defense reaction to MDR-TB patients with HIV as contrasted to MDR-TB patients without HIV. The mid serum level of MCP-3, MIP-1β, IP-10, IFN-γ, and IL-4, was notably dissimilar (p < 0.01) ahead and following medication in the mentioned two groups of patients above. There was no notable variation between MDR-TB patients with HIV and MDR-TB patients without HIV (p > 0.01) in the serum level of any of the chemokines or cytokines ahead of initiation of medicament and second line anti TB drug therapy did not alter the level of any of the assessed cytokines in MDR-TB patients with HIV. From the assessment of this study, second-line anti TB therapy notably improves the Th1 mediators and level of chemokines but does not restore the protection reaction in MDR-TB patients with HIV. MDR-TB patients with HIV or MDR-TB patients without HIV display related serum levels of cytokine and chemokine design.

Keywords: Chemokine, Cytokines, HIV/AIDS, MDR-TB